Proteins > Nuclear receptor corepressor 2
Page last updated: 2024-08-07 18:54:10
Nuclear receptor corepressor 2
A nuclear receptor corepressor 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9Y618]
Synonyms
N-CoR2;
CTG repeat protein 26;
SMAP270;
Silencing mediator of retinoic acid and thyroid hormone receptor;
SMRT;
T3 receptor-associating factor;
TRAC;
Thyroid-, retinoic-acid-receptor-associated corepressor
Research
Bioassay Publications (60)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (1.67) | 29.6817 |
2010's | 42 (70.00) | 24.3611 |
2020's | 17 (28.33) | 2.80 |
Compounds (28)
Drugs with Inhibition Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
ci 994 | Homo sapiens (human) | IC50 | 0.1900 | 1 | 1 |
entinostat | Homo sapiens (human) | IC50 | 1.1850 | 6 | 6 |
entinostat | Homo sapiens (human) | Ki | 0.8225 | 4 | 4 |
scriptaid | Homo sapiens (human) | IC50 | 0.1884 | 2 | 2 |
fenofibrate | Homo sapiens (human) | IC50 | 75.0000 | 1 | 1 |
fenofibrate | Homo sapiens (human) | Ki | 75.0000 | 1 | 1 |
vorinostat | Homo sapiens (human) | IC50 | 0.0905 | 31 | 31 |
vorinostat | Homo sapiens (human) | Ki | 0.0020 | 1 | 1 |
benzohydroxamic acid | Homo sapiens (human) | IC50 | 71.5720 | 1 | 1 |
n-hydroxy-2,2-diphenylacetamide | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
trichostatin a | Homo sapiens (human) | IC50 | 0.0138 | 7 | 7 |
trichostatin a | Homo sapiens (human) | Ki | 0.0006 | 2 | 2 |
romidepsin | Homo sapiens (human) | IC50 | 1.0585 | 8 | 8 |
romidepsin | Homo sapiens (human) | Ki | 0.0249 | 1 | 1 |
psammaplin a | Homo sapiens (human) | IC50 | 0.0124 | 1 | 1 |
tubacin | Homo sapiens (human) | IC50 | 1.2700 | 2 | 2 |
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone | Homo sapiens (human) | IC50 | 0.0193 | 3 | 3 |
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone | Homo sapiens (human) | Ki | 0.0015 | 1 | 1 |
panobinostat | Homo sapiens (human) | IC50 | 0.0020 | 6 | 6 |
n1-(2-aminophenyl)-n7-phenylheptanediamide | Homo sapiens (human) | IC50 | 0.0690 | 1 | 1 |
givinostat | Homo sapiens (human) | IC50 | 0.1360 | 1 | 1 |
mocetinostat | Homo sapiens (human) | IC50 | 0.0450 | 1 | 1 |
quisinostat | Homo sapiens (human) | IC50 | 0.0049 | 3 | 3 |
abexinostat | Homo sapiens (human) | IC50 | 0.1480 | 1 | 1 |
chidamide | Homo sapiens (human) | IC50 | 0.3300 | 1 | 1 |
pci 34051 | Homo sapiens (human) | IC50 | 30.0652 | 3 | 3 |
largazole | Homo sapiens (human) | IC50 | 2.0020 | 1 | 1 |
tubastatin a | Homo sapiens (human) | IC50 | 10.3204 | 8 | 8 |
pracinostat | Homo sapiens (human) | IC50 | 0.0700 | 1 | 1 |
acy-1215 | Homo sapiens (human) | IC50 | 0.0463 | 3 | 3 |
cudc-907 | Homo sapiens (human) | IC50 | 0.0025 | 2 | 2 |
rgfp966 | Homo sapiens (human) | IC50 | 0.2000 | 2 | 2 |
rg2833 | Homo sapiens (human) | IC50 | 0.0630 | 1 | 1 |
rg2833 | Homo sapiens (human) | Ki | 0.0050 | 1 | 1 |
santacruzamate a | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.Bioorganic & medicinal chemistry, , 02-15, Volume: 56, 2022
Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.ACS medicinal chemistry letters, , May-12, Volume: 13, Issue:5, 2022
Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.Journal of medicinal chemistry, , 05-28, Volume: 63, Issue:10, 2020
[no title available]European journal of medicinal chemistry, , Apr-15, Volume: 192, 2020
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.Journal of medicinal chemistry, , 12-26, Volume: 62, Issue:24, 2019
Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.European journal of medicinal chemistry, , Sep-01, Volume: 177, 2019
HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.European journal of medicinal chemistry, , Sep-05, Volume: 157, 2018
Highly fluorescent and HDAC6 selective scriptaid analogues.European journal of medicinal chemistry, , Jan-15, Volume: 162, 2019
Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy.Bioorganic & medicinal chemistry, , 04-01, Volume: 25, Issue:7, 2017
Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.European journal of medicinal chemistry, , Dec-05, Volume: 225, 2021
Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.Bioorganic & medicinal chemistry, , 07-15, Volume: 42, 2021
[no title available]Journal of medicinal chemistry, , 10-28, Volume: 64, Issue:20, 2021
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with Journal of medicinal chemistry, , 03-25, Volume: 64, Issue:6, 2021
Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).Journal of medicinal chemistry, , 04-08, Volume: 64, Issue:7, 2021
Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.Journal of medicinal chemistry, , 05-28, Volume: 63, Issue:10, 2020
Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.European journal of medicinal chemistry, , Apr-15, Volume: 192, 2020
A 18β-glycyrrhetinic acid conjugate with Vorinostat degrades HDAC3 and HDAC6 with improved antitumor effects.European journal of medicinal chemistry, , Feb-15, Volume: 188, 2020
Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.European journal of medicinal chemistry, , Sep-15, Volume: 178, 2019
Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics.Bioorganic & medicinal chemistry, , 10-01, Volume: 27, Issue:19, 2019
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.Journal of medicinal chemistry, , 12-26, Volume: 62, Issue:24, 2019
Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
A fluorine scan on the ZnEuropean journal of medicinal chemistry, , Nov-15, Volume: 182, 2019
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.European journal of medicinal chemistry, , Oct-05, Volume: 158, 2018
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.Journal of medicinal chemistry, , 02-22, Volume: 61, Issue:4, 2018
Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.Bioorganic & medicinal chemistry, , 08-15, Volume: 26, Issue:15, 2018
Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.Bioorganic & medicinal chemistry, , 05-01, Volume: 26, Issue:8, 2018
Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.European journal of medicinal chemistry, , Jan-01, Volume: 143, 2018
Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.Journal of medicinal chemistry, , 07-13, Volume: 60, Issue:13, 2017
Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.European journal of medicinal chemistry, , Apr-13, Volume: 112, 2016
Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors.ACS medicinal chemistry letters, , Mar-12, Volume: 6, Issue:3, 2015
4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.European journal of medicinal chemistry, , Apr-09, Volume: 76, 2014
Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6, 2014
Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 24, Issue:1, 2014
Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.ACS medicinal chemistry letters, , Jun-14, Volume: 3, Issue:6, 2012
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.Journal of medicinal chemistry, , Jul-14, Volume: 54, Issue:13, 2011
Discovery of histone deacetylase 8 selective inhibitors.Bioorganic & medicinal chemistry letters, , May-01, Volume: 21, Issue:9, 2011
Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.ACS medicinal chemistry letters, , Jul-21, Volume: 2, Issue:9, 2011
Development of a fluorescence polarization based assay for histone deacetylase ligand discovery.Bioorganic & medicinal chemistry letters, , May-01, Volume: 18, Issue:9, 2008
Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.Bioorganic & medicinal chemistry, , 02-15, Volume: 56, 2022
Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.European journal of medicinal chemistry, , Feb-01, Volume: 187, 2020
Highly fluorescent and HDAC6 selective scriptaid analogues.European journal of medicinal chemistry, , Jan-15, Volume: 162, 2019
Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor.Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.Journal of medicinal chemistry, , 04-26, Volume: 61, Issue:8, 2018
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.European journal of medicinal chemistry, , Oct-05, Volume: 158, 2018
Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.European journal of medicinal chemistry, , Jun-30, Volume: 116, 2016
Development of a fluorescence polarization based assay for histone deacetylase ligand discovery.Bioorganic & medicinal chemistry letters, , May-01, Volume: 18, Issue:9, 2008
Discovery of HDAC Inhibitors That Lack an Active Site Zn(2+)-Binding Functional Group.ACS medicinal chemistry letters, , Jun-14, Volume: 3, Issue:6, 2012
Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities.Journal of natural products, , Oct-28, Volume: 74, Issue:10, 2011
Development of a fluorescence polarization based assay for histone deacetylase ligand discovery.Bioorganic & medicinal chemistry letters, , May-01, Volume: 18, Issue:9, 2008
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.Journal of medicinal chemistry, , Aug-22, Volume: 56, Issue:16, 2013
Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.Journal of medicinal chemistry, , Sep-26, Volume: 56, Issue:18, 2013
Macrocyclic peptoid-Peptide hybrids as inhibitors of class I histone deacetylases.ACS medicinal chemistry letters, , Sep-13, Volume: 3, Issue:9, 2012
Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ΔF508-CFTR.ACS medicinal chemistry letters, , Jul-21, Volume: 2, Issue:9, 2011
Development of a fluorescence polarization based assay for histone deacetylase ligand discovery.Bioorganic & medicinal chemistry letters, , May-01, Volume: 18, Issue:9, 2008
Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.Journal of medicinal chemistry, , 05-28, Volume: 63, Issue:10, 2020
Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.Journal of medicinal chemistry, , 06-09, Volume: 59, Issue:11, 2016
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with Journal of medicinal chemistry, , 03-25, Volume: 64, Issue:6, 2021
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.Journal of medicinal chemistry, , 11-12, Volume: 63, Issue:21, 2020
Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.Journal of medicinal chemistry, , 10-13, Volume: 59, Issue:19, 2016
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.Journal of medicinal chemistry, , 11-12, Volume: 63, Issue:21, 2020
Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
Design, Synthesis, and Biological Evaluation of Tetrahydroisoquinoline-Based Histone Deacetylase 8 Selective Inhibitors.ACS medicinal chemistry letters, , Aug-10, Volume: 8, Issue:8, 2017
Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy.European journal of medicinal chemistry, , Feb-05, Volume: 229, 2022
[no title available]Journal of medicinal chemistry, , 10-28, Volume: 64, Issue:20, 2021
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.Journal of medicinal chemistry, , 11-12, Volume: 63, Issue:21, 2020
Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.European journal of medicinal chemistry, , Apr-25, Volume: 150, 2018
Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.Journal of medicinal chemistry, , Feb-25, Volume: 59, Issue:4, 2016
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.Journal of medicinal chemistry, , Aug-22, Volume: 56, Issue:16, 2013
Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.Journal of medicinal chemistry, , Sep-26, Volume: 56, Issue:18, 2013
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.Journal of medicinal chemistry, , 11-12, Volume: 63, Issue:21, 2020
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.Journal of medicinal chemistry, , 02-08, Volume: 61, Issue:3, 2018
Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.Bioorganic & medicinal chemistry, , 05-01, Volume: 26, Issue:8, 2018
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.Journal of medicinal chemistry, , 02-22, Volume: 61, Issue:4, 2018
Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.Journal of medicinal chemistry, , 06-09, Volume: 59, Issue:11, 2016
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.Journal of medicinal chemistry, , 12-26, Volume: 62, Issue:24, 2019
Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).Journal of medicinal chemistry, , 03-08, Volume: 61, Issue:5, 2018
Enables
This protein enables 8 target(s):
Target | Category | Definition |
DNA binding | molecular function | Any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid). [GOC:dph, GOC:jl, GOC:tb, GOC:vw] |
chromatin binding | molecular function | Binding to chromatin, the network of fibers of DNA, protein, and sometimes RNA, that make up the chromosomes of the eukaryotic nucleus during interphase. [GOC:jl, ISBN:0198506732, PMID:20404130] |
transcription corepressor activity | molecular function | A transcription coregulator activity that represses or decreases the transcription of specific gene sets via binding to a DNA-bound DNA-binding transcription factor, either on its own or as part of a complex. Corepressors often act by altering chromatin structure and modifications. For example, one class of transcription corepressors modifies chromatin structure through covalent modification of histones. A second class remodels the conformation of chromatin in an ATP-dependent fashion. A third class modulates interactions of DNA-bound DNA-binding transcription factors with other transcription coregulators. [GOC:txnOH-2018, PMID:10213677, PMID:16858867] |
Notch binding | molecular function | Binding to a Notch (N) protein, a surface receptor. [GOC:ceb] |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
nuclear glucocorticoid receptor binding | molecular function | Binding to a nuclear glucocorticoid receptor. [GOC:bf] |
histone deacetylase binding | molecular function | Binding to histone deacetylase. [GOC:jl] |
nuclear retinoid X receptor binding | molecular function | Binding to a nuclear retinoid X receptor. [GOC:ai] |
Located In
This protein is located in 5 target(s):
Target | Category | Definition |
nucleus | cellular component | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. [GOC:go_curators] |
nucleoplasm | cellular component | That part of the nuclear content other than the chromosomes or the nucleolus. [GOC:ma, ISBN:0124325653] |
membrane | cellular component | A lipid bilayer along with all the proteins and protein complexes embedded in it and attached to it. [GOC:dos, GOC:mah, ISBN:0815316194] |
nuclear matrix | cellular component | The dense fibrillar network lying on the inner side of the nuclear membrane. [ISBN:0582227089] |
nuclear body | cellular component | Extra-nucleolar nuclear domains usually visualized by confocal microscopy and fluorescent antibodies to specific proteins. [GOC:ma, PMID:10330182] |
Part Of
This protein is part of 2 target(s):
Target | Category | Definition |
chromatin | cellular component | The ordered and organized complex of DNA, protein, and sometimes RNA, that forms the chromosome. [GOC:elh, PMID:20404130] |
transcription repressor complex | cellular component | A protein complex that possesses activity that prevents or downregulates transcription. [GOC:mah] |
Involved In
This protein is involved in 10 target(s):
Target | Category | Definition |
negative regulation of transcription by RNA polymerase II | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase II. [GOC:go_curators, GOC:txnOH] |
lactation | biological process | The regulated release of milk from the mammary glands and the period of time that a mother lactates to feed her young. [ISBN:0198506732] |
response to organonitrogen compound | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organonitrogen stimulus. An organonitrogen compound is formally a compound containing at least one carbon-nitrogen bond. [PMID:9869419] |
regulation of cellular ketone metabolic process | biological process | Any process that modulates the chemical reactions and pathways involving any of a class of organic compounds that contain the carbonyl group, CO, and in which the carbonyl group is bonded only to carbon atoms. The general formula for a ketone is RCOR, where R and R are alkyl or aryl groups. [GOC:dph, GOC:tb] |
cerebellum development | biological process | The process whose specific outcome is the progression of the cerebellum over time, from its formation to the mature structure. The cerebellum is the portion of the brain in the back of the head between the cerebrum and the pons. In mice, the cerebellum controls balance for walking and standing, modulates the force and range of movement and is involved in the learning of motor skills. [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid, ISBN:0838580343] |
response to estradiol | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by estradiol, a C18 steroid hormone hydroxylated at C3 and C17 that acts as a potent estrogen. [GOC:mah, ISBN:0911910123] |
estrous cycle | biological process | A type of ovulation cycle, which occurs in most mammalian therian females, where the endometrium is resorbed if pregnancy does not occur. [GOC:jl, Wikipedia:Estrous_cycle] |
negative regulation of DNA-templated transcription | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-templated transcription. [GOC:go_curators, GOC:txnOH] |
negative regulation of androgen receptor signaling pathway | biological process | Any process that decreases the rate, frequency, or extent of the androgen receptor signaling pathway. [GOC:dph] |
negative regulation of miRNA transcription | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of microRNA (miRNA) gene transcription. [GO_REF:0000058, GOC:dph, GOC:kmv, GOC:TermGenie, PMID:24699545] |